Open-Label Neoadjuvant Pembrolizumab Plus Cetuximab in Betel Nut-Associated Locally Advanced Oral Cavity Squamous Cell Carcinoma
NCT07733466
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Betel-nut-associated Oral Carcinoma
Interventions
DRUG:
Pembrolizumab and cetuximab
Sponsor
Peter Brett, MD